Top

Published in:

01-05-2008 | original article

Surgical Outcomes in Esophageal Cancer Patients with Tumor Recurrence After Curative Esophagectomy

Authors: Chikara Kunisaki, Hirochika Makino, Ryo Takagawa, Naoto Yamamoto, Yasuhiko Nagano, Syoichi Fujii, Takashi Kosaka, Hidetaka A. Ono, Yuichi Otsuka, Hirotoshi Akiyama, Yasushi Ichikawa, Hiroshi Shimada

Published in: Journal of Gastrointestinal Surgery | Issue 5/2008

Abstract

This study aimed to identify predictive factors and to evaluate appropriate treatments for recurrence of esophageal cancer after curative esophagectomy. About 166 consecutive patients, who underwent curative esophagectomy, were enrolled between April 1994 and March 2003. Recurrence was classified as loco-regional or distant. Logistic regression analysis was used to identify predictive factors for recurrence. Prognostic factors were evaluated by Log-rank test and Cox proportional hazard regression analysis. The disease-specific 5-year survival was 56.8%. Recurrence was observed in 72 patients (43.4%), with 64 of these occurring within 3 years. The number of metastatic lymph nodes and lymphatic invasion independently predicted recurrence. There were significant differences in time to recurrence and survival time between loco-regional, distant recurrence, and combined recurrence. The 5-year survival time in patients with recurrence was 11.9%, and median survival time was 24 months. There was also a significant difference in survival after recurrence between treatment methods (no treatment vs chemo-radiotherapy, p = 0.0063; chemotherapy, p = 0.0247; and radiotherapy, p < 0.0001). Meticulous, long-term follow-up is particularly necessary in patients with four or more metastatic lymph nodes to achieve early detection of recurrence. Randomized controlled trials should be used to develop effective modalities for each recurrence pattern to improve therapeutic outcomes.

Daly JM, Fray WA, Little AG, Winchester DP, McKee RF, Stewart AK, Fremgen AM. Esophageal cancer: results of an American College of Surgeons patient care evaluation study. J Am Coll Surg. 2000;190:562–573.PubMedCrossRef

Lerut T, Nafteux P, Moons J, Coosemans W, Decker G, De Leyn P, Van Raemdonck D, Ectors N. Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg. 2004;240:962–974.PubMedCrossRef

Isono K, Ochiai T, Okuyama K, Onoda S. The treatment of lymph node metastasis esophageal cancer by extensive lymphadenectomy. Jpn J Surg. 1990;20:151–157.PubMedCrossRef

Baba M, Aikou T, Yoshinaka H, Natsugoe S, Fukumoto T, Shimazu H, Akazawa K. Long-term results of subtotal esophagectomy with three-field lymphadenectomy for carcinoma of the thoracic esophagus. Ann Surg. 1994;219:310–316.PubMedCrossRef

Akiyama H, Tsurumaru M, Udagawa H, Kajiyama Y. Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg. 1994;220:364–372.PubMedCrossRef

Law S, Wong J. Two-field dissection is enough for esophageal cancer. Dis Esophagus. 2001;14:98–103.PubMedCrossRef

Kunisaki C, Shimada H, Akiyama H, Nomura M, Matsuda G, Ono H. Prognostic factors in esophageal cancer. Hepato-gastroenterol. 2004;51:736–740.

Osugi H, Takemura M, Takada N, Hirohashi K, Kinoshita H, Higashino M. Prognostic factors after oesophagectomy and extended lymphadenectomy for squamous oesophageal cancer. Br J Surg. 2002;89:909–913.PubMedCrossRef

Wijnhoven BP, Tran KT, Esterman A, Watson DI, Tilanus HW. An evaluation of prognostic factors and tumor staging of resected carcinoma of the esophagus. Ann Surg. 2007;245:717–725.PubMedCrossRef

10.

Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19:305–313.PubMed

11.

Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET, Denham JW, Trans-Tasman Radiation Oncology Group, Australasian Gastro-Intestinal Trials Group. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005;6:659–668.PubMedCrossRef

12.

Pouliquen X, Levard H, Hay JM, McGee K, Fingerhut A, Langlois-Zantin O. 5-Fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicenter randomized trial. French Associations for Surgical Research. Ann Surg. 1996;223:127–133.PubMedCrossRef

13.

Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, Takiyama W, Watanabe H, Isono K, Aoyama N, Makuuchi H, Tanaka O, Yamana H, Ikeuchi S, Kabuto T, Nagai K, Shimada Y, Kinjo Y, Fukuda H. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study–JCOG9204. J Clin Oncol. 2003;21:4592–4596.PubMedCrossRef

14.

Mariette C, Balon JM, Piessen G, Fabre S, Van Seuningen I, Triboulet JP. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer. 2003;97:1616–1623.PubMedCrossRef

15.

Dresner SM, Griffin SM. Pattern of recurrence following radical oesophagectomy with two-field lymphadenectomy. Br J Surg. 2000;87:1426–1433.PubMedCrossRef

16.

Tachibana M, Kinugasa S, Yoshimura H, Shibakita M, Tonomoto Y, Dhar DK, Nagasue N. Clinical outcomes of extended esophagectomy with three-field lymph node dissection for esophageal squamous cell carcinoma. Am J Surg. 2005;189:98–109.PubMedCrossRef

17.

Shimada H, Kitabayashi H, Nabeya Y, Okazumi S, Matsubara H, Funami Y, Miyazawa Y, Shiratori T, Uno T, Itoh H, Ochiai T. Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery. 2003;133:24–31.PubMedCrossRef

18.

Sobin LH, Wittekind CH. TNM: Classification of Malignant Tumours. 6th ed. New York: Wiley-Liss; 2002.

19.

Japanese Society for Esophageal Disease. Guidelines for Clinical and Pathologic Studies on Carcinoma of the Esophagus. 9thth ed. Tokyo: Kanehara; 2001.

20.

Chen G, Wang Z, Liu XY, Liu FY. Recurrence pattern of squamous cell carcinoma in the middle thoracic esophagus after modified Ivor-Lewis esohagectomy. World J Surg. 2007;31:1107–1114.PubMed

21.

Fujita H, Sueyoshi S, Tanaka T, Shirouzu K. Three-field dissection for squamous cell carcinoma in the thoracic esophagus. Ann Thorac Cardiovasc Surg. 2002;8:328–335.PubMed

22.

Altorki N, Kent M, Ferrara C, Port J. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg. 2002;236:177–183.PubMedCrossRef

23.

Nakagawa S, Kanda T, Kosugi S, Ohashi M, Suzuki T, Hatakeyama K. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg. 2004;198:205–211.PubMedCrossRef

24.

Osugi H, Takemura M, Higashino M, Takada N, Lee S, Ueno M, Tanaka Y, Fukuhara K, Hashimoto Y, Fujiwara Y, Kinoshita H. Causes of death and pattern of recurrence after esophagectomy and extended lymphadenectomy for squamous cell carcinoma of the thoracic esophagus. Oncol Rep. 2003;10:81–87.PubMed

25.

O’sullivan GC, Sheehan D, Clarke A, Stuart R, Kelly J, Kiely MD, Walsh T, Collins JK, Shanahan F. Micrometastases in esophagogastric cancer: high detection rate in resected rib segments. Gastroenterology. 1999;116:543–548.PubMedCrossRef

26.

Ajani J, Bekaii-Saab T, Gibson MK, Osarogiagbon RU. NCCN practice guidelines for esophageal cancer (Version 2.2007). http://www.nccn.org.

27.

Gondi V, Bradley K, Mehta M, Howard A, Khuntia D, Ritter M, Tomé W. Impact of hybrid fluorodeoxyglucose positron-emission tomography/computed tomography on radiotherapy planning in esophageal and non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2007;67:187–195.PubMed

28.

Wong WL, Chambers RJ. Role of PET/PET CT in the staging and restaging of thoracic oesophageal cancer and gastro-oesophageal cancer: a literature review. Abdom Imaging 2007 DOI 10.1007/s00261-007-9241-1.

29.

Kitagawa Y, Kitajima M. Gastrointestinal cancer and sentinel node navigation surgery. J Surg Oncol. 2002;79:188–193.PubMedCrossRef

30.

Arima H, Natsugoe S, Uenosono Y, Arigami T, Ehi K, Yanagita S, Higashi H, Ishigami S, Hokita S, Aikou T. Area of nodal metastasis and radioisotope uptake in sentinel nodes of upper gastrointestinal cancer. J Surg Res. 2006;135:250–254.PubMedCrossRef

Title: Surgical Outcomes in Esophageal Cancer Patients with Tumor Recurrence After Curative Esophagectomy
Authors: Chikara Kunisaki
Hirochika Makino
Ryo Takagawa
Naoto Yamamoto
Yasuhiko Nagano
Syoichi Fujii
Takashi Kosaka
Hidetaka A. Ono
Yuichi Otsuka
Hirotoshi Akiyama
Yasushi Ichikawa
Hiroshi Shimada
Publication date: 01-05-2008
Publisher: Springer-Verlag
Published in: Journal of Gastrointestinal Surgery / Issue 5/2008
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-007-0385-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Surgical Outcomes in Esophageal Cancer Patients with Tumor Recurrence After Curative Esophagectomy

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2008

Complications of PTFE Mesh at the Diaphragmatic Hiatus

Conservative Management of Adhesive Small Bowel Obstructions in Patients Previously Operated on for Primary Colorectal Cancer

Albendazole is Not Effective for Primary Treatment of Hepatic Hydatid Cysts

Retroportal Hepaticojejunostomy for Extended Resection of Hilar Bile Ducts

Operative Mortality After Hepatic Resection: Are Literature-Based Rates Broadly Applicable?

Inclusion of Tumor Markers Improves the Correlation of the Milan Criteria with Vascular Invasion and Tumor Cell Differentiation in Patients with Hepatocellular Carcinoma Undergoing Liver Resection (#JGSU-D-07–00462)